The primary objective of the study is to evaluate the effectiveness of fremanezumab as
compared to placebo for the preventive treatment of chronic migraine (CM).
Secondary objectives are to further demonstrate the efficacy of Fremanezumab as compared to
placebo for the preventive treatment of CM, to evaluate the safety and tolerability of
Fremanezumab in the preventive treatment of CM and to evaluate the immunogenicity of
Fremanezumab and the impact of antidrug antibodies (ADAs) on clinical outcomes in
participants exposed to Fremanezumab
The total duration of the study is planned to be 48 months.

A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Patients 6 to 17 Years of Age

Colorado Springs

Teva Investigational Site 14368

Fremanezumab

Placebo

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age

This phase III trial studies how well atezolizumab added to the usual radiation therapy works
in treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with
monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation
therapy, such as stereotactic body radiation therapy, uses special equipment to position a
patient and deliver radiation to tumors with high precision. This method can kill tumor cells
with fewer doses over a shorter period and cause less damage to normal tissue. Giving
atezolizumab and radiation therapy may work better than radiation therapy alone in treating
patients with early non-small cell lung cancer.

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

Memorial Hospital North

Atezolizumab

Biospecimen Collection

Quality-of-Life Assessment

Questionnaire Administration

Stereotactic Body Radiation Therapy

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

This study will investigate the effect of tirzepatide on the reduction of morbidity and
mortality in adults living with obesity and provide additional evidence for the potential
clinical benefits of tirzepatide in this population.

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Optum- Southwestern

Tirzepatide

A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity

This study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared
with placebo in patients with International Society of Nephrology/Renal Pathology Society
(ISN/RPS) class III or IV lupus nephritis (LN) when added on to standard-of-care therapy
consisting of mycophenolate mofetil (MMF) and corticosteroids.

A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis

El Paso

Texas Arthritis Center

Obinutuzumab

Prednisone

Methylprednisolone

Acetaminophen

Diphenhydramine

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)

This clinical research study investigates the safety and tolerability of a peanut
SLIT-tablet.

Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

Western Sky Medical Research

Peanut SLIT-tablet

A Phase I, Open-label Trial to Assess the Tolerability and Safety of an Up-dosing Regimen With a Once-daily Peanut SLIT-tablet in Adults, Adolescents, and Children With Peanut Allergy

This phase II/III trial compares the addition of radiation therapy to the usual treatment
(immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating
patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes
(advanced) or has spread to other places in the body (metastatic) whose tumor is also
negative for a molecular marker called PD-L1. Stereotactic body radiation therapy (SBRT) is a
type of radiation therapy that uses high energy x-rays to kill tumor cells and shrink tumors.
This method uses special equipment to position a patient and precisely deliver radiation to
tumors with fewer doses over a shorter period and may cause less damage to normal tissue than
conventional radiation therapy. Immunotherapy with monoclonal antibodies, such as nivolumab,
ipilimumab and pembrolizumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as
carboplatin, pemetrexed, paclitaxel and nab-paclitaxel, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. The addition of radiation therapy to usual treatment may stop
the cancer from growing and increase the life of patients with advanced non-small cell lung
cancer who are PD-L1 negative.

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative

Carboplatin

Computed Tomography

Ipilimumab

Magnetic Resonance Imaging

Nab-paclitaxel

Nivolumab

Paclitaxel

Pembrolizumab

Pemetrexed

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer

The purpose of this study is to test the long-term safety of rimegepant in the acute
treatment of moderate or severe migraine in children and adolescents (≥ 6 to < 18 years of
age).

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

ANRC Research

Rimegepant / BHV3000

Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to <18 Years of Age.

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in
the acute treatment of moderate or severe migraine in children and adolescents.

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Rimegepant/BHV3000

Matching placebo

Phase 3, Multicenter, Randomized, Double-blind,Group Sequential, Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to <18 Years of Age

The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a))
levels among participants with a history of ASCVD as defined by their medical history and is
2-fold:
-  Evaluate the distribution of Lp(a) value in the overall participants with documented
history of ASCVD
-  Evaluate the distribution of Lp(a) value in participants with documented history of
ASCVD by demographics and regions

A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

UCHealth Memorial Central

Lp(a) Screening

A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease

This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention
in adults who suffer from six or more migraine days per month. The study will enroll 765
patients across approximately 64 sites in the United States, Canada and Australia. Study
subjects will be divided evenly across a low dose group, a high dose group and a placebo
group. All patients will receive two treatment cycles of ABP-450 or placebo utilizing the
Company's novel injection paradigm.

Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Delta Waves LLC - Hunt - PPDS

ABP-450

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache

El Paso, Texas

El Paso

< 500 mi

A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Patients 6 to 17 Years of Age

< 500 mi

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

< 500 mi

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

< 5 mi

A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis

< 5 mi

Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

< 500 mi

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative

< 5 mi

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

< 5 mi

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

< 500 mi

A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

< 500 mi

Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults